Osel Sees Immunotherapy-Like Trajectory For Oncology Microbiome Candidate
Executive Summary
Depending on financing, the company could start a Phase III trial of CBM588 as early as this year, but it’s looking to develop the microbiome therapeutic for a potentially broad array of cancers.
You may also be interested in...
Early Success For 4D Pharma’s Microbiome Plus Keytruda Combination
After years of halting progress in its microbiome-based pipeline, 4D Pharma has produced promising early data from its cancer immunotherapy combination.
Boehringer Snaps Up T3 Amid Broader Immuno-Oncology Push
The German drug maker is spending CHF450m to acquire T3, which is focused on developing live bacteria to treat cancers.
Merck & Co. Seeds Neuroscience Expansion With Caraway Buy
The drug maker will spend up to $610m to acquire Caraway, with a lead product candidate targeting TRPML1, a pathway implicated in a number of neurodegenerative diseases.